Page 1514 - Hematology_ Basic Principles and Practice ( PDFDrive )

1342.e4 Part VII Hematologic Malignancies

lymphomas after allogeneic hematopoietic cell transplantation. Blood 141. Metzger ML, Weinstein HJ, Hudson MM, et al: Association between
119:2644, 2012. radiotherapy vs no radiotherapy based on early response to VAMP che-
121. Swinnen LJ: Diagnosis and treatment of transplant-related lymphoma motherapy and survival among children with favorable-risk Hodgkin
2. Ann Oncol 11(Suppl 1):45, 2000. lymphoma. JAMA 307:2609, 2012.
122. Pakakasama S, Eames GM, Morriss MC, et al: Treatment of Epstein- 142. Friedman DL, Whitton J, Leisenring W, et al: Subsequent neoplasms in
Barr virus lymphoproliferative disease after hematopoietic stem-cell 5-year survivors of childhood cancer: the Childhood Cancer Survivor
transplantation with hydroxyurea and cytotoxic T-cell lymphocytes. Study. J Natl Cancer Inst 102:1083, 2010.
Transplantation 78:755, 2004. 143. Kelly KM, Hodgson D, Appel B, et al: Children’s Oncology Group’s
123. Gross TG, Bucuvalas JC, Park JR, et al: Low-dose chemotherapy for 2013 blueprint for research: Hodgkin lymphoma. Pediatr Blood Cancer
Epstein-Barr virus-positive post-transplantation lymphoproliferative 60:972, 2013.
disease in children after solid organ transplantation. J Clin Oncol 144. Younes A, Gopal AK, Smith SE, et al: Results of a pivotal phase II
23:6481, 2005. study of brentuximab vedotin for patients with relapsed or refractory
124. Gross TG, Orjuela MA, Perkins SL, et al: Low-dose chemotherapy Hodgkin’s lymphoma. J Clin Oncol 30:2183, 2012.
and rituximab for posttransplant lymphoproliferative disease (PTLD): 144a. Donaldson SS, Link MP, Weinstein HJ, et al: Final results of a prospec-
a Children’s Oncology Group report. Am J Transplant 12:3069, tive clinical trial with VAMP and low-dose involved-field radiation for
2012. children with low-risk Hodgkin’s disease. J Clin Oncol 25(3):332–337,
125. Bollard CM, Gottschalk S, Torrano V, et al: Sustained complete 2007.
responses in patients with lymphoma receiving autologous cytotoxic T 145. Lieskovsky YE, Donaldson SS, Torres MA, et al: High-dose therapy
lymphocytes targeting Epstein-Barr virus latent membrane proteins. J and autologous hematopoietic stem-cell transplantation for recurrent or
Clin Oncol 32:798, 2014. refractory pediatric Hodgkin’s disease: results and prognostic indices. J
126. Montella M, Maso LD, Crispo A, et al: Do childhood diseases affect Clin Oncol 22:4532, 2004.
NHL and HL risk? A case-control study from northern and southern 146. Bradley MB, Cairo MS: Stem cell transplantation for pediatric lym-
Italy. Leuk Res 30:917, 2006. phoma: past, present and future. Bone Marrow Transplant 41:149,
127. Kennedy-Nasser AA, Hanley P, Bollard CM: Hodgkin disease and the 2008.
role of the immune system. Pediatr Hematol Oncol 28:176, 2011. 147. Ladenstein R, Pearce R, Hartmann O, et al: High-dose chemotherapy
128. Biggar RJ, Jaffe ES, Goedert JJ, et al: Hodgkin lymphoma and immu- with autologous bone marrow rescue in children with poor-risk
nodeficiency in persons with HIV/AIDS. Blood 108:3786, 2006. Burkitt’s lymphoma: a report from the European Lymphoma Bone
129. Schnitzer B: Hodgkin lymphoma. Hematol Oncol Clin North Am Marrow Transplantation Registry. Blood 90:2921, 1997.
23:747, 2009. 148. Sandlund JT, Bowman L, Heslop HE, et al: Intensive chemotherapy
130. Pileri SA, Ascani S, Leoncini L, et al: Hodgkin’s lymphoma: the with hematopoietic stem-cell support for children with recurrent or
pathologist’s viewpoint. J Clin Pathol 55:162, 2002. refractory NHL. Cytotherapy 4:253, 2002.
131. Lister TA, Crowther D, Sutcliffe SB, et al: Report of a committee con- 149. Loiseau HA, Hartmann O, Valteau D, et al: High-dose chemotherapy
vened to discuss the evaluation and staging of patients with Hodgkin’s containing busulfan followed by bone marrow transplantation in 24
disease: Cotswolds meeting. J Clin Oncol 7:1630, 1989. children with refractory or relapsed non-Hodgkin’s lymphoma. Bone
132. Dunleavy K, Bollard CM: Sobering realities of surviving Hodgkin Marrow Transplant 8:465, 1991.
lymphoma. Blood 117:1772, 2011. 150. Claviez A, Sureda A, Schmitz N: Haematopoietic SCT for children and
133. Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D, et al: Resection adolescents with relapsed and refractory Hodgkin’s lymphoma. Bone
alone in 58 children with limited stage, lymphocyte-predominant Marrow Transplant 42(Suppl 2):S16, 2008.
Hodgkin lymphoma—experience from the European network group 151. Sureda A, Constans M, Iriondo A, et al: Prognostic factors affect-
on pediatric Hodgkin lymphoma. Cancer 110:179, 2007. ing long-term outcome after stem cell transplantation in Hodgkin’s
134. Mauz-Körholz C, Hasenclever D, Dorffel W, et al: Procarbazine-free lymphoma autografted after a first relapse. Ann Oncol 16:625,
OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in 2005.
girls have comparable effectiveness in pediatric Hodgkin’s lymphoma: 152. Majhail NS, Weisdorf DJ, DeFor TE, et al: Long-term results of
the GPOH-HD-2002 study. J Clin Oncol 28:3680, 2010. autologous stem cell transplantation for primary refractory or relapsed
135. Friedman DL, Chen L, Wolden S, et al: Dose-intensive response-based Hodgkin’s lymphoma. Biol Blood Marrow Transplant 12:1065,
chemotherapy and radiation therapy for children and adolescents with 2006.
newly diagnosed intermediate-risk Hodgkin lymphoma: a report from 153. Shafer JA, Heslop HE, Brenner MK, et al: Outcome of hematopoietic
the Children’s Oncology Group Study AHOD0031. J Clin Oncol stem cell transplant as salvage therapy for Hodgkin’s lymphoma in
32:3651, 2014. adolescents and young adults at a single institution. Leuk Lymphoma
136. Schwartz CL, Constine LS, Villaluna D, et al: A risk-adapted, response- 51:664, 2010.
based approach using ABVE-PC for children and adolescents with 154. Peniket AJ, Ruiz de Elvira MC, Taghipour G, et al: An EBMT registry
intermediate- and high-risk Hodgkin lymphoma: the results of P9425. matched study of allogeneic stem cell transplants for lymphoma: alloge-
Blood 114:2051, 2009. neic transplantation is associated with a lower relapse rate but a higher
137. Keller H, Goda JS, Vines DC, et al: Quantification of local tumor procedure-related mortality rate than autologous transplantation. Bone
response to fractionated radiation therapy for non-Hodgkin lymphoma Marrow Transplant 31:667, 2003.
using weekly F-FDG PET/CT imaging. Int J Radiat Oncol Biol Phys 155. Gutman JA, Bearman SI, Nieto Y, et al: Autologous transplantation
18
76:850, 2010. followed closely by reduced-intensity allogeneic transplantation as con-
138. Tebbi CK, Mendenhall NP, London WB, et al: Response-dependent solidative immunotherapy in advanced lymphoma patients: a feasibility
and reduced treatment in lower risk Hodgkin lymphoma in children study. Bone Marrow Transplant 36:443, 2005.
and adolescents, results of P9426: a report from the Children’s Oncol- 156. Claviez A, Klingebiel T, Beyer J, et al: Allogeneic peripheral blood
ogy Group. Pediatr Blood Cancer 59:1259, 2012. stem cell transplantation following fludarabine-based conditioning in
139. Wolden SL, Chen L, Kelly KM, et al: Long-term results of CCG six children with advanced Hodgkin’s disease. Ann Hematol 83:237,
5942: a randomized comparison of chemotherapy with and without 2004.
radiotherapy for children with Hodgkin’s lymphoma—a report from 157. Pardoll DM: Immunology beats cancer: a blueprint for successful
the Children’s Oncology Group. J Clin Oncol 30:3174, 2012. translation. Nat Immunol 13:1129, 2012.
140. Landman-Parker J, Pacquement H, Leblanc T, et al: Localized 158. Ansell SM, Lesokhin AM, Borrello I, et al: PD-1 blockade with niv-
childhood Hodgkin’s disease: response-adapted chemotherapy with olumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med
etoposide, bleomycin, vinblastine, and prednisone before low-dose 372:311, 2015.
radiation therapy-results of the French Society of Pediatric Oncology 159. Bollard CM, Gottschalk S, Leen AM, et al: Complete responses of
Study MDH90. J Clin Oncol 18:1500, 2000. relapsed lymphoma following genetic modification of tumor-antigen